.jpg){kind=logo}
Cell and gene therapies (CGTs) harness the power of a patient’s own immune system to treat or, in some cases, even cure a variety of previously untreatable diseases. Currently, the market size is estimated at 18.12B, with projected growth to 82.24B by 2032.1 The explosive growth can be primarily attributed to the significant increase in FDA-approved treatments over the past 2 decades. In 2024 alone, as many as 31 gene therapy launches are expected including more than 29 adeno-associate virus (AAV) therapies.2
The Gene Therapy Summit will give detailed insights and industry best practices as Johnson & Johnson Innovation looks to what the future may hold for gene therapies. Our experts will discuss the challenges and opportunities that lie ahead in this area of rapid growth.
Hear from thought leaders from the West Coast, including disease area and platform experts from Johnson & Johnson. Panel sessions will focus on a range of scientific advancements across the early stage academic and biotech ecosystem, as well as effective academic-industry collaborations to accelerate innovation, investment, commercialization, and capacity-building for this next generation of innovative medicines.
9:00AM Registration Opens
9:30AM Opening Remarks | Stacy A. Feld
Welcoming remarks by Johnson & Johnson, with highlights of the symposium program.
9:45AM Keynote | David Schaffer, Ph.D.
A deep dive into the promise and challenges of gene therapy, including building ecosystems, partnering across academia and industry, and accelerating innovation to improve patient outcomes.
10:15AM Break
10:30AM Spotlight on Research Advancements: Academic Research Showcase
Leading researchers will deliver presentations on their current groundbreaking projects in gene therapy. Explore the forefront of this innovative field with insightful talks by experts in the region.
Presenters
Le Cong, Ph.D.
David J. Segal, Ph.D.
Amanda M. Dudek, Ph.D.*
11:30AM Spotlight on Johnson & Johnson Programs: Our Vision for Gene Therapy
Three enlightening spotlight presentations followed by a panel discussion that pull back the curtain on how a large pharmaceutical company thinks about the next generation of gene therapy technologies. Delve into their visionary approach, shedding light on the future of gene therapy.
Presenters
Thomas Wechsler, Ph.D.
Krista Spiller, Ph.D.
Mohammad Harun-Or-Rashid, Ph.D., M.Sc, BPharm
12:15PM Luncheon
1:00PM The JLABS Difference | Chris Haskell, Ph.D.
JLABS @ SSF Site Head Chris Haskell will give a brief overview of our partnering capabilities as Johnson & Johnson Innovation, with a spotlight on our JLABS facility in South San Francisco.
1:05PM Spotlight on Pioneering the Path from Bench to Bedside
Early-stage biotech experts will delve into the transformative process of translating cutting-edge genetic research into life-changing therapies, bridging the gap between scientific innovation and real-world patient care.
Presenters
Will Mueller, Ph.D.
Megan Blewett, Ph.D.
Benjamin Oakes, Ph.D.*
2:25PM Break
2:45PM Spotlight on the Ever-Evolving Gene Therapy Field
A conversation on navigating and overcoming challenges in the gene therapy innovation lifecycle. Our panel of industry leaders and experts will share their invaluable insights, strategies, and experiences in tackling obstacles to ensure the continuous progression of gene therapy innovation within corporate settings.
Panelists
Michael Holmes, Ph.D.*
Nathalie Dubois-Stringfellow, Ph.D.*
Sharyl Fyffe-Maricich, Ph.D.
Morten Sogaard, Ph.D.*